Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 10/20 | 0.92 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.92 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.92 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.92 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.92 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.92 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.92 |
| ▸ | RHOC | P08134 | 1/20 | 0.92 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.92 |
| ▸ | THRB | P10828 | 1/20 | 0.92 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.92 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.92 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.81 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.81 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.81 |
| ▸ | PDE6D | O43924 | 3/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.54 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms241423 SCHEMBL4785660 | 1.00 | HMGCR (0.92) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL6769237 | 0.97 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL28548478 | 0.97 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL6761283 | 0.96 | HMGCR (0.97) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL8257670 | 0.96 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL3056792 | 0.96 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL465015 | 0.96 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL13900412 | 0.96 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| SCHEMBL21637576 | 0.96 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL6266705 | 0.96 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263786-A1 | MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT | AKEBIA THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | US | claimed |
| EP-4181873-A1 | MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT | Akebia Therapeutics Inc. (US) | 2023-05-24 | — | — | EP | claimed |
| CN-111812217-B | Method for detecting concentration of antiatherosclerotic drug in blood plasma | 南京品生医学检验实验室有限公司 | 2022-09-16 | — | — | CN | claimed |
| CN-114740125-A | LC-MS-based 10 cardiovascular drug serum detection method and kit | 杭州度安医学检验实验室有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111184717-A | Composition containing mixture of pyrrolyl dihydroxy heptanoic acid derivatives and use thereof | 黄泳华 | 2020-05-22 | — | — | CN | claimed |
| EP-0680963-B1 | (Hydroxyphenylamino)carbonyl pyrroles | WARNER LAMBERT CO (US) | 2001-11-21 | — | — | EP | claimed |
| EP-0680963-A1 | (Hydroxyphenylamino)carbonyl pyrroles | WARNER-LAMBERT COMPANY (US) | 1995-11-08 | — | — | EP | claimed |
| US-5385929-A | Anticholesterol agents | WARNER-LAMBERT COMPANY (US) | 1995-01-31 | — | — | US | claimed |
| US-20250064767-A1 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | ESPERION THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20240148681-A1 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | ESPERION THERAPEUTICS INC (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4327887-A2 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | Esperion Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3270909-B1 | FIXED DOSE COMBINATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS FOR TREATING OR REDUCING CARDIOVASCULAR RISK | ESPERION THERAPEUTICS INC (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116832164-A | Fixed dose combinations comprising ETC1002 and statins | 艾斯柏伦治疗公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| CN-111184717-A | Composition containing mixture of pyrrolyl dihydroxy heptanoic acid derivatives and use thereof | 黄泳华 | 2020-05-22 | — | — | CN | disclosed |
| WO-2012061165-A2 | METHODS AND COMPOSITIONS FOR IMPROVING ADMET PROPERTIES | LU XIANDAN SHARON (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-0680963-B1 | (Hydroxyphenylamino)carbonyl pyrroles | WARNER LAMBERT CO (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-0680963-A1 | (Hydroxyphenylamino)carbonyl pyrroles | WARNER-LAMBERT COMPANY (US) | 1995-11-08 | — | — | EP | disclosed |
| US-5385929-A | Anticholesterol agents | WARNER-LAMBERT COMPANY (US) | 1995-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263786-A1 | MODULATION OF DRUG-DRUG INTERACTIONS OF VADADUSTAT | SLC5A6, CACNA1D, STIM1 | HMGCR 9/4885SLCO1B1 29/4885ABCB11 533/4885 |
| US-20250064767-A1 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | APOB, GOT2, PCSK9 | HMGCR 4/4885SLCO1B1 939/4885ABCB11 1173/4885 |
| US-20240148681-A1 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | APOB, GOT2, PCSK9 | HMGCR 4/4885SLCO1B1 939/4885ABCB11 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.